Rehovot, Israel – July 29, 2020 – Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading artificial intelligence company targeting to revolutionize life-science product development across several market segments utilizing computational biology, announces today that Ofer Haviv, Evogene’s President and CEO, will present at the Jefferies Virtual 2020 Industrials Conference taking place on August 5-6, 2020. Mr. Haviv’s presentation will focus on the application of Evogene’s technology, the CPB platform, in the area of ag-chemicals and ag-biologicals and will take place on Thursday, August 6, at 08:00 am, EST.
Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene’s Investor Relations team at firstname.lastname@example.org or through the conference’s online meeting platform.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN, TASE: EVGN.TA) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
For more information, please visit www.evogene.com
Forward Looking Statements:
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses the end-to-end solutions provided by the system to be developed and the expansion of the Company’s artificial intelligence capabilities and solutions. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene’s reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
|Evogene Investor Contact:||
US Investor Relations:
Investor Relations and Public Relations Manager
T: +1 646-653-7030
T: +1 646-653-7035